Prostate Cancer
Prostate Cancer
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
Prostate Cancer
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Patient AdvocacyPatient StoriesProstate Cancer
Dennis Golden was an active, fit, 70-year-old when he learned he had prostate cancer. He was surprised to discover that few men know the warning signs and how potentially serious it can be. In response, he formed the National Prostate Cancer Awareness Foundation to educate men about this disease.
Patient StoriesProstate Cancer
By Greg Kelly
Retiree Greg Kelly has a passion and affinity for model building.
Prostate Cancer
Frank dela Rama explains the options available today, the limitations, and possibilities in the future for the diagnosis of prostate cancer.
Prostate Cancer
Oncology navigator Frank dela Rama lists the screening tools available now for diagnosing prostate cancer.
Prostate Cancer
Frank dela Rama talks about some of the stigma and miscommunication surrounding prostate cancer screening and the need for clarity.
Prostate Cancer
Frank dela Rama explains the current recommendations for screening for prostate cancer.
Patient StoriesProstate Cancer
A doctor’s mistake left Richard Churchill reeling, but during treatment for prostate cancer he found solace in nature and in many new relationships with patients, caregivers, and family members.
FDA Approvals, News & UpdatesNewsworthyProstate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17